X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2806) 2806
Publication (214) 214
Newsletter (92) 92
Book Review (19) 19
Newspaper Article (18) 18
Magazine Article (11) 11
Conference Proceeding (3) 3
Paper (3) 3
Book Chapter (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2085) 2085
rosuvastatin calcium (1859) 1859
index medicus (1635) 1635
male (1600) 1600
rosuvastatin (1568) 1568
female (1293) 1293
middle aged (1085) 1085
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (1083) 1083
fluorobenzenes - therapeutic use (988) 988
statins (951) 951
sulfonamides - therapeutic use (944) 944
pyrimidines - therapeutic use (941) 941
aged (807) 807
atorvastatin (661) 661
cardiac & cardiovascular systems (630) 630
pharmacology & pharmacy (624) 624
cholesterol (564) 564
treatment outcome (559) 559
adult (536) 536
animals (527) 527
cholesterol, ldl - blood (461) 461
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (459) 459
antilipemic agents (443) 443
fluorobenzenes - pharmacology (432) 432
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (428) 428
simvastatin (428) 428
sulfonamides - pharmacology (414) 414
fluorobenzenes - administration & dosage (412) 412
pyrimidines - pharmacology (412) 412
pyrimidines - administration & dosage (392) 392
sulfonamides - administration & dosage (388) 388
atorvastatin calcium (374) 374
risk factors (373) 373
atherosclerosis (350) 350
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (349) 349
pravastatin (319) 319
risk (307) 307
hypercholesterolemia - drug therapy (296) 296
fluorobenzenes - adverse effects (287) 287
cardiovascular (286) 286
medicine, general & internal (284) 284
pyrimidines - adverse effects (277) 277
sulfonamides - adverse effects (276) 276
c-reactive protein (274) 274
dose-response relationship, drug (272) 272
lipids (270) 270
rats (267) 267
analysis (259) 259
cardiovascular diseases - prevention & control (259) 259
cardiovascular disease (255) 255
abridged index medicus (253) 253
hypercholesterolemia (251) 251
therapy (249) 249
heptanoic acids - therapeutic use (244) 244
pyrroles - therapeutic use (243) 243
prevention (238) 238
coronary-heart-disease (231) 231
double-blind method (230) 230
statin therapy (230) 230
drug therapy (226) 226
research (225) 225
rosuvastatin calcium - therapeutic use (223) 223
statin (222) 222
inflammation (220) 220
anticholesteremic agents - therapeutic use (218) 218
peripheral vascular disease (215) 215
disease (212) 212
prospective studies (208) 208
drug therapy, combination (206) 206
pharmacokinetics (204) 204
dosage and administration (203) 203
time factors (201) 201
care and treatment (198) 198
cardiovascular-disease (188) 188
biomarkers - blood (184) 184
low density lipoproteins (178) 178
simvastatin - therapeutic use (178) 178
cardiovascular diseases (175) 175
randomized controlled trials as topic (175) 175
safety (173) 173
efficacy (171) 171
aged, 80 and over (168) 168
mortality (168) 168
density-lipoprotein cholesterol (166) 166
cholesterol - blood (162) 162
fluorobenzenes - pharmacokinetics (162) 162
dyslipidemias - drug therapy (159) 159
mice (159) 159
follow-up studies (158) 158
hydroxymethylglutaryl-coa reductase inhibitors - pharmacokinetics (155) 155
c-reactive protein - metabolism (153) 153
cholesterol, hdl - blood (153) 153
rosuvastatin calcium - administration & dosage (153) 153
internal medicine (152) 152
drug interactions (151) 151
lipids - blood (151) 151
oxidative stress (151) 151
nutritional and metabolic diseases (149) 149
primary prevention (147) 147
pyrimidines - pharmacokinetics (146) 146
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2771) 2771
Russian (43) 43
Chinese (24) 24
German (16) 16
Italian (16) 16
Spanish (13) 13
French (9) 9
Japanese (7) 7
Swedish (7) 7
Dutch (5) 5
Hungarian (5) 5
Ukrainian (5) 5
Turkish (4) 4
Portuguese (2) 2
Czech (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Colloids and Surfaces B: Biointerfaces, ISSN 0927-7765, 12/2013, Volume 112, pp. 337 - 343
The aim of the present study is to improve solubility and bioavailability of Rosuvastatin calcium using self nanoemulsifying drug delivery system (SNEDDS).... 
Rosuvastatin calcium | Pharmacokinetic study | Bioavailability | SNEDDS | Poorly water soluble drug | Self nanoemulsifying drug delivery system | MATERIALS SCIENCE, BIOMATERIALS | Self nanoemulsifying drug delivery system SNEDDS | DISPERSION | RATS | CHEMISTRY, PHYSICAL | ORAL ABSORPTION | TABLETS | IN-VITRO | BIOPHYSICS | DISSOLUTION | ENHANCED ABSORPTION | OPTIMIZATION | EMULSIFYING SYSTEM | HPLC | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Fluorobenzenes - pharmacokinetics | Chemistry, Pharmaceutical - methods | Emulsions | Rats, Wistar | Pyrimidines - blood | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Biological Availability | Male | Fluorobenzenes - administration & dosage | Chromatography, High Pressure Liquid | Drug Carriers - chemistry | Drug Delivery Systems | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Fluorobenzenes - blood | Surface-Active Agents | Oils | Pyrimidines - administration & dosage | Solubility | Rats | Rosuvastatin Calcium | Sulfonamides - pharmacokinetics | Particle Size | Animals | Membrane Potentials | Nanostructures - chemistry | Pyrimidines - pharmacokinetics | Sulfonamides - administration & dosage | Drugs | Drugstores | Drug delivery systems | Analysis | Antilipemic agents | Vehicles | Calcium | Zeta potential | Mathematical models | Droplets | Nanostructure
Journal Article
Journal of Cellular and Molecular Medicine, ISSN 1582-1838, 12/2012, Volume 16, Issue 12, pp. 3052 - 3061
There are controversies concerning the capacity of Rosuvastatin to attenuate heart failure in end‐stage hypertension. The aim of the study was to show whether... 
heart failure | protein kinase Cα/β2 | sarcoplasmic reticulum calcium pump | spontaneously hypertensive rat | sodium–calcium exchanger | Rosuvastatin | phospholamban | ryanodine receptor2 | Heart failure | Sodium-calcium exchanger | Spontaneously hypertensive rat | Protein kinase Cα/β2 | Sarcoplasmic reticulum calcium pump | Phospholamban | Ryanodine receptor2 | Up-Regulation | Phosphorylation | Protein Kinase C-alpha - metabolism | Ryanodine Receptor Calcium Release Channel - biosynthesis | Myofibrils - pathology | Sarcoplasmic Reticulum - drug effects | Rats, Inbred WKY | Hypertension - drug therapy | Male | Proteins - analysis | Electron Transport Complex IV - metabolism | RNA, Messenger - biosynthesis | Sodium-Calcium Exchanger - biosynthesis | Peptide Fragments - blood | Aging | Blood Pressure - drug effects | Natriuretic Peptide, Brain - blood | Rats, Inbred SHR | Myofibrils - drug effects | Natriuretic Peptide, Brain - genetics | Sarcoplasmic Reticulum Calcium-Transporting ATPases - metabolism | Calcium-Binding Proteins - biosynthesis | Signal Transduction | Down-Regulation | Ventricular Function, Left - drug effects | Rats | Rosuvastatin Calcium | Stroke Volume - drug effects | Calcium-Calmodulin-Dependent Protein Kinase Type 2 - biosynthesis | Mitochondria - metabolism | Mitochondria - pathology | Heart Failure - drug therapy | Animals | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Sarcoplasmic Reticulum - pathology | Protein Kinase C beta - metabolism | Fluorobenzenes - therapeutic use | Cytochrome | Heart | Protein kinase C | Calcium | Cytochrome-c oxidase | Ryanodine receptors | Kinases | Ca2+-transporting ATPase | Proteins | Na+/Ca2+-exchanging ATPase | Mitochondria | Sarcoplasmic reticulum | Calcium-binding protein | Conflicts of interest | Blood pressure | Heart diseases | Calmodulin | Failure | Hypertension | Cardiovascular system | Brain natriuretic peptide | Gene expression | Myofibrils | Sodium | Protein phosphatase inhibitors | Myocardium | Cytochromes | Protein phosphatase | Ventricle | Laboratory animals | NCX1 protein | Calcium (reticular) | Calcium ions | Ejection | Ca2+/calmodulin-dependent protein kinase II | protein kinase Cα | Original
Journal Article
Synthesis, ISSN 0039-7881, 12/2016, Volume 48, Issue 23, pp. 4167 - 4174
Abstract A novel asymmetric synthesis of a (3 R ,5 S )-dihydroxyhexanoic ester is described. The ester, which serves as the precursor for generating the side... 
paper | d -glucose | diastereoselective reduction | Wittig olefination | sugar chemistry | lactone reduction | rosuvastatin calcium | total synthesis | COA REDUCTASE INHIBITOR | ROUTE | MOIETY | ACID | CROSS-COUPLING REACTION | ENANTIOSELECTIVE SYNTHESIS | CHEMISTRY, ORGANIC | D-glucose | STATINS | NK-104 | INTERMEDIATE | STEREOSELECTIVE-SYNTHESIS
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9792, pp. 684 - 692
Summary Background The JUPITER trial showed that some patients with LDL-cholesterol concentrations less than 3·37 mmol/L (<130 mg/dL) and high-sensitivity... 
Internal Medicine | ALL-CAUSE MORTALITY | MEDICINE, GENERAL & INTERNAL | DENSITY-LIPOPROTEIN CHOLESTEROL | HEART-DISEASE | MEN | TRIAL EVALUATING ROSUVASTATIN | RISK | SUBCLINICAL ATHEROSCLEROSIS | INTERVENTION | COMPUTED-TOMOGRAPHY | PRIMARY PREVENTION | Calcium - metabolism | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Tomography, X-Ray Computed | Coronary Vessels - metabolism | Coronary Disease - metabolism | Aged, 80 and over | Cholesterol, LDL - blood | Female | C-Reactive Protein - analysis | Cardiovascular Diseases - diagnosis | Cardiovascular Diseases - metabolism | Risk Assessment | Coronary Artery Disease - metabolism | Risk Factors | Coronary Artery Disease - prevention & control | Rosuvastatin Calcium | Coronary Disease - diagnosis | Coronary Disease - prevention & control | Sulfonamides - therapeutic use | Coronary Artery Disease - diagnosis | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Survival Analysis | Aged | Fluorobenzenes - therapeutic use | C-reactive protein | Physiological aspects | Rosuvastatin | Research | Cardiovascular diseases | Drug therapy | Health aspects | Heart attacks | Mortality | Risk assessment | Atherosclerosis | Colleges & universities | Cardiovascular disease | Triglycerides | Cost control | Calcification (ectopic) | Heart | mesas | Calcium | Lung | Clinical trials | Population studies | Coronary heart disease | Blood | Proteins | resource allocation | Arteriosclerosis | statins
Journal Article
European Journal of Organic Chemistry, ISSN 1434-193X, 07/2017, Volume 2017, Issue 25, pp. 3681 - 3688
The stereocontrolled synthesis of atorvastatin calcium starting from commercially available d‐ aspartic acid using an intramolecular oxidative... 
Bromine | Medicinal chemistry | Inhibitors | Asymmetric synthesis | Cyclization | PITAVASTATIN CALCIUM | ROSUVASTATIN CALCIUM | SIDE-CHAIN | STRATEGY | HMG-COA REDUCTASE | EFFICIENT SYNTHESIS | CHEMISTRY, ORGANIC | CHEMOENZYMATIC SYNTHESIS | BETA-HYDROXYKETONES | STEREOSELECTIVE-SYNTHESIS | Aspartate | Synthesis | Organic compounds | Antilipemic agents
Journal Article
Journal of Heterocyclic Chemistry, ISSN 0022-152X, 05/2017, Volume 54, Issue 3, pp. 1898 - 1903
A novel and efficient five‐step synthetic route, including a Biginelli reaction, dehydrogenation, chlorination, sulfonamidation, and reduction, for the core of... 
CHEMISTRY, ORGANIC | STATINS | DIHYDROPYRIMIDINES | Cytokinins | Rosuvastatin | Dehydrogenation | Antilipemic agents
Journal Article
Chinese Journal of New Drugs, ISSN 1003-3734, 05/2018, Volume 27, Issue 9, pp. 1058 - 1064
Journal Article
International Journal of Clinical Pharmacology and Therapeutics, ISSN 0946-1965, 2017, Volume 55, Issue 3, pp. 286 - 294
Context: A fixed-dose combination (FDC) of candesartan and rosuvastatin was recently developed for the treatment of cardiovascular disease and expected to... 
Rosuvastatin calcium | Candesartan cilexetil | Bioequivalence study | Angiotensin receptor blocker | Fixed-dose combination | HMG-CoA reductase | EFFICACY | rosuvastatin calcium | VOLUNTEERS | angiotensin receptor blocker | OPEN-LABEL | fixed-dose combination | STATINS | candesartan cilexetil | bioequivalence study | 2-PERIOD | PHARMACOLOGY & PHARMACY | CROSSOVER | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Angiotensin II Type 1 Receptor Blockers - adverse effects | Tablets | Area Under Curve | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Antihypertensive Agents - administration & dosage | Biphenyl Compounds - adverse effects | Half-Life | Male | Metabolic Clearance Rate | Healthy Volunteers | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Rosuvastatin Calcium - administration & dosage | Tetrazoles - blood | Young Adult | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Adult | Biphenyl Compounds - blood | Benzimidazoles - adverse effects | Rosuvastatin Calcium - blood | Benzimidazoles - blood | Republic of Korea | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Biphenyl Compounds - pharmacokinetics | Administration, Oral | Rosuvastatin Calcium - pharmacokinetics | Benzimidazoles - pharmacokinetics | Antihypertensive Agents - pharmacokinetics | Antihypertensive Agents - adverse effects | Antihypertensive Agents - blood | Cross-Over Studies | Asian Continental Ancestry Group | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Biphenyl Compounds - administration & dosage | Angiotensin II Type 1 Receptor Blockers - blood | Tetrazoles - adverse effects | Drug Combinations | Tetrazoles - pharmacokinetics | Therapeutic Equivalency | Pharmaceutical industry
Journal Article
Tetrahedron Letters, ISSN 0040-4039, 06/2017, Volume 58, Issue 26, pp. 2614 - 2617
During the process development for multistep synthesis of Rosuvastatin calcium several impurities were obtained along with the final Rosuvastatin calcium. Out... 
Rosuvastatin calcium | Drug impurities | HMG-CoA reductase inhibitor | β-Hydroxy sulfonamide | Statins | THERAPY | EFFICACY | SAFETY | BIOLOGICAL-ACTIVITY | CHEMISTRY, ORGANIC | beta-Hydroxy sulfonamide | HYPERCHOLESTEROLEMIA | HYPERTRIGLYCERIDEMIA | Antilipemic agents | Drugstores | Rosuvastatin | Sulfonamides | Pharmacy
Journal Article
Colloids and Surfaces B: Biointerfaces, ISSN 0927-7765, 05/2019, Volume 177, pp. 541 - 549
Biological events encountered upon oral administration of surface modified phospholipid-based self-nanoemulsifying drug delivery systems The present work... 
Phospholipids | Bioavailability | Hyperlipidemia | Nanomedicines | Solubility | DESIGN | MATERIALS SCIENCE, BIOMATERIALS | DELIVERY SYSTEMS SNEDDS | VIVO | ENHANCED BIOAVAILABILITY | CHEMISTRY, PHYSICAL | PHOSPHOLIPID COMPLEX | LONG-CHAIN | IN-VITRO | BIOPHYSICS | ORAL DELIVERY | SELF-NANOEMULSIFYING FORMULATION | OILY FORMULATIONS | Drugs | Drug delivery systems | Rosuvastatin | Permeability | Vehicles
Journal Article
Drug Development and Industrial Pharmacy, ISSN 0363-9045, 10/2019, Volume 45, Issue 10, pp. 1635 - 1645
Objective: The aim of the study was to formulate, cyclodextrin (CD)-polyanhydride (PA) nanoparticles (CPNs) with rosuvastatin calcium (RCa) in order to enhance... 
Rosuvastatin calcium | polyanhydride nanoparticles | bioavailability | cyclodextrins | inclusion complexes
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 3/2015, Volume 71, Issue 3, pp. 341 - 355
Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure... 
SLCO1B1 | Pharmacogenetics | Biomedicine | Caucasian | Pharmacology/Toxicology | Pharmacokinetics | Asian | ABCG2 | WHITE | ADULT MALE-VOLUNTEERS | RISK | OATP1B1 | DISPOSITION | MARKEDLY AFFECTS | TRANSPORT | SYSTEMIC EXPOSURE | DISEASE | PHARMACOLOGY & PHARMACY | HEALTHY-VOLUNTEERS | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Simvastatin - adverse effects | Atorvastatin Calcium - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Asian Continental Ancestry Group - genetics | Male | Simvastatin - blood | Young Adult | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Organic Anion Transporters - genetics | ATP-Binding Cassette Transporters - genetics | Adult | Female | Neoplasm Proteins - genetics | Rosuvastatin Calcium - blood | Atorvastatin Calcium - adverse effects | Atorvastatin Calcium - pharmacokinetics | European Continental Ancestry Group - genetics | Rosuvastatin Calcium - pharmacokinetics | Genotype | Simvastatin - pharmacokinetics | Simvastatin - analogs & derivatives | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Adolescent | Polymorphism, Single Nucleotide - genetics | Aged | Solute Carrier Organic Anion Transporter Family Member 1b1 | Genetic aspects | Rosuvastatin | Simvastatin | Antilipemic agents | Genotype & phenotype | Whites | Pharmacology | Statins | Asians | Polymorphism
Journal Article
INTERNATIONAL JOURNAL OF NANOMEDICINE, ISSN 1178-2013, 2019, Volume 14, pp. 4625 - 4636
Journal Article